Base-case cost-effectiveness of vitamin D3 supplementation in older adults with vitamin D deficiency plus results of univariate and multivariate sensitivity analyses
| Description | Age group | Net average cost of vitamin D deficiency treatment programme per annum | Discounted QALYs gained | Cost-effectiveness (cost/QALY) |
| Base-case | ≥50 years | €25 207 905 | 1691 | €14 911 |
| ≥60 years | €14 039 487 | 1447 | €9702 | |
| ≥70 years | €5 607 144 | 1044 | €5371 | |
| Increasing the serum 25(OH)D measurement cost by 50% | ≥50 years | €29 959 397 | 1691 | €17 722 |
| ≥60 years | €16 918 458 | 1447 | €11 692 | |
| ≥70 years | €7 007 603 | 1044 | €6712 | |
| Increasing the average end-of-life invasive cancer cost by 50% | ≥50 years | €24 925 167 | 1691 | €14 744 |
| ≥60 years | €13 775 381 | 1447 | €9520 | |
| ≥70 years | €5 382 234 | 1044 | €5155 | |
| Increasing the average annual cost of serum 25(OH)D measurement, GP visit, plus vitamin D3 supplementation acquisition cost by 50% | ≥50 years | €39 425 029 | 1691 | €23 321 |
| ≥60 years | €22 653 769 | 1447 | €15 655 | |
| ≥70 years | €9 797 513 | 1044 | €9385 | |
| ‘Pessimistic’ multivariate sensitivity analysis | ≥50 years | €38 954 948 | 1184 | €32 910 |
| ≥60 years | €22 701 074 | 1013 | €22 405 | |
| ≥70 years | €10 150 658 | 729 | €13 917 |
.25(OH)D, serum 25-hydroxyvitamin D; QALY, quality-adjusted life year.